Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year dose range-finding study of SCH 527123 in moderate to severe COPD
2008-003780-38Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of navarixin in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in post-bronchodilator FEV1. Started Aug 2009; status: completed.
02
Drugs
navarixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-003780-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003780-38.